PMID- 24648686
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140320
LR  - 20211021
IS  - 1013-9087 (Print)
IS  - 2005-3894 (Electronic)
IS  - 1013-9087 (Linking)
VI  - 26
IP  - 1
DP  - 2014 Feb
TI  - Combined treatment of murine fibrosarcoma with chemotherapy (Paclitaxel), 
      radiotherapy, and intratumoral injection of dendritic cells.
PG  - 53-60
LID - 10.5021/ad.2014.26.1.53 [doi]
AB  - BACKGROUND: New antitumor therapeutic strategies aim to combine different 
      approaches that are able to induce tumor-specific effector and memory T cell 
      responses that might control tumor growth. Dendritic cells (DCs) have the 
      capacity to induce antigen-specific cytotoxic T lymphocytes. We have previously 
      shown that the combined treatment of paclitaxel chemotherapy (Chemo) and 
      injection of DCs led to complete tumor regression. OBJECTIVE: The goal of this 
      study was to evaluate synergistic antitumor effect of a triple combination 
      treatment comprising radiotherapy, paclitaxel Chemo and intratumoral injection of 
      syngeneic bone marrow-derived DCs on murine fibrosarcoma, compared to other 
      single or double combination treatments. METHODS: For the murine fibrosarcoma 
      model, naive C57BL/6 mice were inoculated intradermally with 2x10(3) MCA102 cells 
      in the right upper flank. Mice were assigned to five groups (untreatedcontrol, RT 
      alone, RT+Chemo, RT+DC, and RT+Chemo+DC), with eight mice in each group. In vitro 
      cytotoxicity assays were performed to assess the immune activity. The persistence 
      of tumor-specific immunity was determined by second tumor challenge in mice with 
      complete tumor regression. RESULTS: The triple combination treatment showed a 
      significantly enhanced therapeutic efficacy by decreasing tumor size and inducing 
      complete tumor regression, resulting in a cure of 50% of mice. The results of in 
      vitro cytotoxicity assays and the second tumor challenge experiment strongly 
      indicated the induction of a tumor-specific cytotoxic T lymphocyte response and 
      acquisition of prolonged tumor immunity. CONCLUSION: These findings suggest that 
      the triple combination treatment can be a promising strategy for the treatment of 
      murine fibrosarcoma.
FAU - Byun, Ji-Won
AU  - Byun JW
AD  - Department of Dermatology, Inha University School of Medicine, Incheon, Korea.
FAU - Lee, Hyeon-Sook
AU  - Lee HS
AD  - Department of Dermatology, Inha University School of Medicine, Incheon, Korea.
FAU - Song, Sun-Uk
AU  - Song SU
AD  - Clinical Research Center, Inha University School of Medicine, Incheon, Korea.
FAU - Lee, Si-Won
AU  - Lee SW
AD  - Saybeauty Clinic, Incheon, Korea.
FAU - Kim, Soon-Ki
AU  - Kim SK
AD  - Clinical Research Center, Inha University School of Medicine, Incheon, Korea.
FAU - Kim, Woo-Chul
AU  - Kim WC
AD  - Department of Radiation Oncology, Inha University School of Medicine, Incheon, 
      Korea.
FAU - Lee, Moon-Hee
AU  - Lee MH
AD  - Department of Hemato-Oncology, Inha University School of Medicine, Incheon, 
      Korea.
FAU - Choi, Gwang-Seong
AU  - Choi GS
AD  - Department of Dermatology, Inha University School of Medicine, Incheon, Korea.
LA  - eng
PT  - Journal Article
DEP - 20140217
PL  - Korea (South)
TA  - Ann Dermatol
JT  - Annals of dermatology
JID - 8916577
PMC - PMC3956795
OTO - NOTNLM
OT  - Combined modality therapy
OT  - Dendritic cells
OT  - Fibrosarcoma
OT  - Paclitaxel
OT  - Radiotherapy
EDAT- 2014/03/22 06:00
MHDA- 2014/03/22 06:01
PMCR- 2014/02/01
CRDT- 2014/03/21 06:00
PHST- 2012/09/17 00:00 [received]
PHST- 2012/12/12 00:00 [revised]
PHST- 2013/01/05 00:00 [accepted]
PHST- 2014/03/21 06:00 [entrez]
PHST- 2014/03/22 06:00 [pubmed]
PHST- 2014/03/22 06:01 [medline]
PHST- 2014/02/01 00:00 [pmc-release]
AID - 10.5021/ad.2014.26.1.53 [doi]
PST - ppublish
SO  - Ann Dermatol. 2014 Feb;26(1):53-60. doi: 10.5021/ad.2014.26.1.53. Epub 2014 Feb 
      17.